Home Infusion Therapy Market - Forecasts from 2023 to 2028

The global home infusion therapy market was valued at US$32.781 billion in 2021.

The home infusion therapy market is anticipated to grow at a steady pace throughout the forecast period. Home infusion is just one of the many pharmaceutical treatments that are generally offered to patients in their homes as outpatient care. The bulk of these medications must be provided via a needle or catheter, a process known as an infusion; however, some can also be given intramuscularly, epidurally, or using self-injectable devices. Multiple associated benefits of home infusion therapy coupled with the increasing immobility disorders are major growth drivers in the home infusion therapy market. Moreover, the higher rate of hospital-acquired infections and government regulation to encourage home therapy are further contemplated to boost the home infusion therapy market.

Multiple Associated Benefits of Home Infusion Therapy

Home infusion therapy offers a wider range of benefits to patients that encourage its adoption and thereby boost the home infusion therapy market. Studies demonstrate that patients are highly satisfied with home infusion therapy and that clinical results are more positive at home than in inpatient hospital settings. Depending on an individual's healthcare plan, it can be less expensive than receiving the same service at a hospital or clinic. Moreover, with 78% of customers indicating they would be very or somewhat inclined to employ alternative types of treatment, such as a clinician visiting the home, according to EverNorth Health Services, there has been an increase in the demand for more flexibility and choice in how care is given in recent years. The patients' inclination towards home care coupled with associated benefits is contemplated to propel the home infusion therapy market.

Increasing Immobility Disorders

The increasing cases of immobility disorders restraining physical movement indicate the growing demand for home infusion therapy. For instance, there are 1.3 billion persons who are severely disabled. This equates to 1 in 6 of us, or 16% of the world's population as per WHO updates in March 2023. According to the WHO, Accessible and inexpensive transit is 15 times more difficult to find for people with disabilities than it is for people without impairments. Therefore, these immobility disorders are expected to positively impact the home infusion therapy market as it offers a convenient at-home setting to the patients.

Need for Reducing Stays at Hospital

Numerous infections occur when a person stays longer at the hospital and home infusion therapy helps to reduce the infections acquired from the hospitals. According to the WHO, Seven patients in high-income nations and 15 patients in low- and middle-income countries are expected to contract at least one healthcare-associated infection (HAI) during their hospital stay per 100 patients in acute-care hospitals. Every ten people who are impacted will die as a result of their HAI, on average. Newborns and those in critical care are particularly vulnerable and the WHO 2022 study finds that over half of all instances of sepsis with organ failure are treated in adult intensive-care units and about one in four hospital-treated sepsis cases are related to medical care. These hospital-acquired infections pose a problem and therefore encourage the adoption of the home infusion therapy market.

Opportunities in the Market

The growth drivers mentioned above indicate an immense opportunity for the home infusion therapy market. Moreover, government regulations are also providing a growth opportunity in the home infusion therapy market. For instance, in 2021, the Centres for Medicare & Medicaid Services (CMS) passed new regulations that increased the coverage of home infusion therapy to cover a variety of related nursing and monitoring services in addition to the treatment itself. Moreover, Eitan Medical launched a new cutting-edge connected infusion multi-therapy ambulatory infusion system named Avoset™ to transform post-acute care and speciality infusion therapy. Additionally, the approvals of home infusion therapy by the authorities further propel the home infusion therapy market thereby providing an entrance opportunity. For instance, home infusion of anticancer therapy was approved by the ASCO board of directors in June 2020.

Restraints in the Market

There are a few complexities that are supposed to restrain the home infusion therapy market. For example, home infusion pharmacies, patients, doctors, hospital discharge planners, health insurance, and other parties must work closely together to complete the procedure because it can be a complex ecology. Disconnected data poses a significant problem because there are so many parties involved and it can lead to a variety of prescribing, administering, and/or coding problems. For instance, the physician normally submits prior authorization requests and prescription claims, but they go through the plan separately.

North America is projected to Grow Significantly

The North American region is anticipated to hold a significant share of the home infusion therapy market during the forecasted period. Various factors attributed to such a share are increasing immobility disorders, chronic diseases such as cancer, and the aging population along with the favorable government regulations to encourage home infusion therapy. For instance, 12.1 percent of adult U.S. citizens have a mobility impairment that makes walking and climbing stairs extremely difficult and 12.8 percent of adults in the United States struggle greatly with concentration, memory, and decision-making as per the recent CDC data. Moreover, the market players such as Baxter, and Braun Melsungen AG are further expected to propel the home infusion therapy market in the region.

Home Infusion Therapy Market Players

Baxter International is a US-based healthcare company with a portfolio including acute, nutritional, renal, hospital, and surgical care products. The company provides a portfolio of intravenous premixed medication and injectable drugs that are ready to fill patients' needs.

Ambulatory surgery centers, employed physician networks, two HMOs, and 15 hospitals are all part of McLaren Health Care. The Joint Commission (JCAHO) and the Community Health Accreditation Programme (CHAP) have both granted accreditation to McLaren's home infusion service.

Key Market Developments

• In April 2022, AmericsourceBergon (AB) launched a program designed to help hospitals and health systems to launch home infusion service lines. It serves to strengthen program strategy, business operations, and logistics in home infusion therapy.
• In August 2021, HealthIV, a new company focused on home infusion was launched to curb dehydration and hangovers. The company has a digital platform that enables users to book an online appointment for a nurse to come to the home for home infusion therapy.
• In November 2021, The Hospital Clinic Haematology and Oncology Institute (ICMHO) launched an immunotherapy home infusion program for solid organ cancer patients and immunotherapy treatment. It carries out periodical lab tests, administers drugs at patients' homes, and health education.

Segmentation:

By Product

• Infusion Pump Sets
• Accessories and Consumables

By Application

• Total Parenteral Nutrition
• Anti-infective Therapy
• Enteral Nutrition
• Hydration Therapy
• Chemotherapy
• IVIg/Specialty Pharmaceuticals
• Other Applications

By Route of Administration

• Intramuscular
• Subcutaneously
• Epidural

By Geography

• North America
  • United States
  • Canada
  • Mexico

• South America
  • Brazil
  • Argentina
  • Others

• Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others

• The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others

• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others